Literature DB >> 8162502

Mucin expression by transitional cell carcinomas of the bladder.

M D Walsh1, B G Hohn, W Thong, P L Devine, R A Gardiner, M L Samaratunga, M A McGuckin.   

Abstract

OBJECTIVE: To examine the presence of a membrane-associated and secreted mucin (MUC1) and a secreted gel-forming mucin (MUC2) in normal and malignant urothelium.
MATERIALS AND METHODS: Sections were obtained from archival paraffin blocks from 11 patients with nonmalignant urological conditions and 89 patients with transitional cell carcinomas (TCC). Mucin expression was examined by immunohistochemistry using monoclonal antibodies BC2 and 4F1, reactive with epitopes on the protein core of MUC1 and MUC2 respectively.
RESULTS: In normal urothelium MUC1 was limited predominantly to the apical membranes of the umbrella cell layer. MUC1 was present in all cases of TCC, and the pattern of expression divided into three categories: luminal membrane staining only, luminal plus cytoplasmic staining of intermediate +/- basal layers, or staining of only isolated cells or cell groups. These staining patterns were significantly associated with both tumour grade and stage (P < 0.001), with cytoplasmic staining more prevalent in higher grade and stage tumours. MUC2 was not detected in normal urothelium, and was present in 40% of cases of TCC, characterized by intense granular cytoplasmic staining. No association between MUC2 expression and either tumour grade or stage was demonstrated.
CONCLUSION: MUC1 mucin was expressed by both normal and malignant urothelium, with increased expression characteristic of higher grade and stage tumours. MUC2 expression was found in 40% of tumours but not in normal urothelium. The role of these mucins in the biology of the bladder requires further investigation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8162502     DOI: 10.1111/j.1464-410x.1994.tb07514.x

Source DB:  PubMed          Journal:  Br J Urol        ISSN: 0007-1331


  17 in total

1.  Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.

Authors:  S J Pettit; S Ali; E O'Flaherty; T R Griffiths; D E Neal; J A Kirby
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

2.  Invasive urothelial carcinoma with chordoid features of the ureter: a rare entity and review of literature.

Authors:  Jianguo Wei; Zhenying Yue; Dianhang Song; Qiang Wang; Xiaodong Teng
Journal:  Int J Clin Exp Pathol       Date:  2015-11-01

Review 3.  Targeted therapies in urothelial carcinoma.

Authors:  Monalisa Ghosh; Sam J Brancato; Piyush K Agarwal; Andrea B Apolo
Journal:  Curr Opin Oncol       Date:  2014-05       Impact factor: 3.645

Review 4.  Evolving immunotherapy strategies in urothelial cancer.

Authors:  Sam J Brancato; Keidren Lewi; Piyush K Agarwal
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

Review 5.  Tecemotide: an antigen-specific cancer immunotherapy.

Authors:  Gregory T Wurz; Chiao-Jung Kao; Michael Wolf; Michael W DeGregorio
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

6.  Upregulated expression of complement inhibitory proteins on bladder cancer cells and anti-MUC1 antibody immune selection.

Authors:  Juan Carlos Varela; Carl Atkinson; Robert Woolson; Thomas E Keane; Stephen Tomlinson
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

Review 7.  Current status of mucins in the diagnosis and therapy of cancer.

Authors:  Satyanarayana Rachagani; Maria P Torres; Nicolas Moniaux; Surinder K Batra
Journal:  Biofactors       Date:  2009 Nov-Dec       Impact factor: 6.113

8.  Prognostic significance of mucin expression in urothelial bladder cancer.

Authors:  Slavica Stojnev; Ana Ristic-Petrovic; Ljubinka Jankovic Velickovic; Miljan Krstic; Dragan Bogdanovic; Do Throng Khanh; Ana Ristic; Irena Conic; Vladisav Stefanovic
Journal:  Int J Clin Exp Pathol       Date:  2014-07-15

9.  Induction of invasive transitional cell bladder carcinoma in immune intact human MUC1 transgenic mice: a model for immunotherapy development.

Authors:  Daniel P Vang; Gregory T Wurz; Stephen M Griffey; Chiao-Jung Kao; Audrey M Gutierrez; Gregory K Hanson; Michael Wolf; Michael W DeGregorio
Journal:  J Vis Exp       Date:  2013-10-30       Impact factor: 1.355

Review 10.  MUC1 in carcinoma-host interactions.

Authors:  K Denda-Nagai; T Irimura
Journal:  Glycoconj J       Date:  2000 Jul-Sep       Impact factor: 3.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.